loading
Lexicon Pharmaceuticals Inc stock is traded at $0.8247, with a volume of 249.51K. It is up +2.77% in the last 24 hours and down -57.45% over the past month. Lexicon Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in the discovery, development, and commercialization of pharmaceutical products for the treatment of human diseases. Some of its drug candidates are LX9211, an orally-delivered small molecule drug candidate, as a treatment for neuropathic pain; and sotagliflozin, an orally-delivered small molecule drug candidate, as a treatment for heart failure and type 1 diabetes.
See More
Previous Close:
$0.8074
Open:
$0.8043
24h Volume:
249.51K
Relative Volume:
0.08
Market Cap:
$311.01M
Revenue:
$1.21M
Net Income/Loss:
$-177.12M
P/E Ratio:
-1.2127
EPS:
-0.68
Net Cash Flow:
$-162.37M
1W Performance:
-21.72%
1M Performance:
-57.45%
6M Performance:
-50.31%
1Y Performance:
-23.17%
1-Day Range:
Value
$0.8014
$0.8346
1-Week Range:
Value
$0.7942
$1.08
52-Week Range:
Value
$0.7942
$3.73

Lexicon Pharmaceuticals Inc Stock (LXRX) Company Profile

Name
Name
Lexicon Pharmaceuticals Inc
Name
Phone
(281) 863-3000
Name
Address
2445 TECHNOLOGY FOREST BLVD., THE WOODLANDS
Name
Employee
285
Name
Twitter
@LexPharma
Name
Next Earnings Date
2024-11-06
Name
Latest SEC Filings
Name
LXRX's Discussions on Twitter

Compare LXRX with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
LXRX 0.8263 311.01M 1.21M -177.12M -162.37M -0.68
VRTX 448.31 115.74B 10.63B -479.80M -1.35B 13.33
REGN 744.75 81.65B 13.85B 4.65B 3.32B 35.06
ARGX 589.91 34.86B 1.86B -40.29M -1.28B -4.16
ALNY 249.68 32.09B 2.09B -332.26M 16.06M -4.14
BNTX 102.52 24.49B 3.30B -501.07M 1.03B 11.54

Lexicon Pharmaceuticals Inc Stock (LXRX) Upgrades & Downgrades

Date Action Analyst Rating Change
Mar-07-23 Initiated Jefferies Hold
Aug-12-22 Initiated Piper Sandler Overweight
Jan-29-21 Upgrade JP Morgan Underweight → Neutral
Jan-29-21 Downgrade Wedbush Outperform → Neutral
Dec-08-20 Upgrade Citigroup Neutral → Buy
Nov-18-20 Upgrade Gabelli & Co Hold → Buy
Dec-11-19 Downgrade Gabelli & Co Buy → Hold
Nov-08-19 Downgrade Citigroup Buy → Neutral
Sep-11-19 Upgrade Gabelli & Co Hold → Buy
Jul-29-19 Downgrade Stifel Buy → Hold
Mar-25-19 Upgrade Gabelli & Co Sell → Hold
Jul-31-18 Reiterated Stifel Buy
Feb-23-18 Downgrade Needham Buy → Hold
Feb-14-18 Downgrade JP Morgan Neutral → Underweight
Mar-01-17 Reiterated H.C. Wainwright Buy
Mar-01-17 Reiterated Wedbush Outperform
Oct-07-16 Initiated H.C. Wainwright Buy
Aug-05-16 Reiterated Wedbush Outperform
Aug-02-16 Initiated Citigroup Buy
Mar-02-16 Reiterated Wedbush Outperform
Nov-09-15 Reiterated Wedbush Outperform
Sep-28-15 Upgrade Gabelli & Co Sell → Hold
Sep-18-15 Downgrade Gabelli & Co Hold → Sell
Aug-10-15 Downgrade JP Morgan Overweight → Neutral
View All

Lexicon Pharmaceuticals Inc Stock (LXRX) Latest News

pulisher
01:01 AM

Lexicon Appoints Ivan Cheung to Board of Directors - citybiz

01:01 AM
pulisher
Nov 20, 2024

Lexicon Pharmaceuticals appoints Ivan Cheung to board - Investing.com India

Nov 20, 2024
pulisher
Nov 20, 2024

Lexicon Pharma (LXRX) Appoints Ivan H. Cheung to its Board - StreetInsider.com

Nov 20, 2024
pulisher
Nov 20, 2024

Lexicon Pharmaceuticals, Inc. Announces Board Changes - Marketscreener.com

Nov 20, 2024
pulisher
Nov 20, 2024

Lexicon Pharmaceuticals (LXRX) Stock Plummets Amidst Market Acti - GuruFocus.com

Nov 20, 2024
pulisher
Nov 18, 2024

Lexicon Pharmaceuticals (NASDAQ:LXRX investor three-year losses grow to 80% as the stock sheds US$107m this past week - Yahoo Finance

Nov 18, 2024
pulisher
Nov 18, 2024

Leerink Partnrs Has Positive Estimate for LXRX Q4 Earnings - MarketBeat

Nov 18, 2024
pulisher
Nov 15, 2024

Lexicon Pharmaceuticals stock hits 52-week low at $1 - Investing.com India

Nov 15, 2024
pulisher
Nov 15, 2024

What is HC Wainwright's Forecast for LXRX FY2024 Earnings? - MarketBeat

Nov 15, 2024
pulisher
Nov 14, 2024

Post-Hoc Analysis Demonstrating Sotagliflozin Benefits Across Broad Spectrum of Heart Failure Patient Populations is Among Four Lexicon-Supported Presentations at the American Heart Association's (AHA) Sessions 2024 in Chicago - The Manila Times

Nov 14, 2024
pulisher
Nov 14, 2024

Lexicon's Sotagliflozin Shows Strong Benefits Across All Heart Failure Stages in New Data | LXRX Stock News - StockTitan

Nov 14, 2024
pulisher
Nov 13, 2024

Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Q3 2024 Earnings Call Transcript - Insider Monkey

Nov 13, 2024
pulisher
Nov 13, 2024

HC Wainwright Reaffirms Buy Rating for Lexicon Pharmaceuticals (NASDAQ:LXRX) - MarketBeat

Nov 13, 2024
pulisher
Nov 13, 2024

Needham & Company LLC Reiterates Hold Rating for Lexicon Pharmaceuticals (NASDAQ:LXRX) - MarketBeat

Nov 13, 2024
pulisher
Nov 13, 2024

Demystifying Lexicon Pharmaceuticals: Insights From 10 Analyst Reviews - Benzinga

Nov 13, 2024
pulisher
Nov 13, 2024

Lexicon Pharmaceuticals Inc (LXRX) Q3 2024 Earnings Call Highlig - GuruFocus.com

Nov 13, 2024
pulisher
Nov 13, 2024

Lexicon Pharmaceuticals Inc (LXRX) Q3 2024 Earnings Call Highlights: Strategic Advances Amidst ... - Yahoo Finance

Nov 13, 2024
pulisher
Nov 13, 2024

Lexicon: Q3 Earnings Snapshot - The Washington Post

Nov 13, 2024
pulisher
Nov 13, 2024

FMR LLC's Strategic Acquisition of Lexicon Pharmaceuticals Shares - GuruFocus.com

Nov 13, 2024
pulisher
Nov 12, 2024

LXRXLexicon Pharmaceuticals, Inc. Latest Stock News & Market Updates - StockTitan

Nov 12, 2024
pulisher
Nov 12, 2024

Lexicon Pharmaceuticals (LXRX) Reports Q3 Loss, Lags Revenue Estimates - Yahoo Finance

Nov 12, 2024
pulisher
Nov 12, 2024

Lexicon Pharmaceuticals Inc (LXRX) Q3 2024 Earnings: EPS of -$0. - GuruFocus.com

Nov 12, 2024
pulisher
Nov 12, 2024

Lexicon Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Update - The Manila Times

Nov 12, 2024
pulisher
Nov 12, 2024

Lexicon Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com

Nov 12, 2024
pulisher
Nov 11, 2024

Lexicon Pharmaceuticals Inc (LXRX) Q3 2024 Earnings Report Previ - GuruFocus.com

Nov 11, 2024
pulisher
Nov 11, 2024

Lexicon Pharmaceuticals Inc (LXRX) Q3 2024 Earnings Report Preview: What To Look For - Yahoo Finance

Nov 11, 2024
pulisher
Nov 06, 2024

Lexicon Pharmaceuticals (LXRX) to Release Quarterly Earnings on Tuesday - MarketBeat

Nov 06, 2024
pulisher
Nov 06, 2024

Lexicon Pharmaceuticals to Participate in the Jefferies London Global Healthcare Conference - The Manila Times

Nov 06, 2024
pulisher
Nov 06, 2024

Lexicon Pharmaceuticals CEO to Present at Jefferies London Healthcare Conference | LXRX Stock News - StockTitan

Nov 06, 2024
pulisher
Nov 05, 2024

The Analyst Landscape: 11 Takes On Lexicon Pharmaceuticals - Benzinga

Nov 05, 2024
pulisher
Nov 05, 2024

HC Wainwright Reiterates Buy Rating for Lexicon Pharmaceuticals (NASDAQ:LXRX) - MarketBeat

Nov 05, 2024
pulisher
Nov 05, 2024

Lexicon Pharmaceuticals to Host Third Quarter 2024 Financial Results Conference Call and Webcast on November 12, 2024 - The Manila Times

Nov 05, 2024
pulisher
Nov 04, 2024

Pharma Stock Has Significant Upside Potential, Analyst Says - Streetwise Reports

Nov 04, 2024
pulisher
Nov 04, 2024

Lexicon to Present Preclinical IN VIVO Efficacy Data Demonstrating Ability of New Investigational Compound to Enhance and Maintain Semaglutide-Promoted Weight Loss - StockTitan

Nov 04, 2024
pulisher
Nov 03, 2024

Lexicon Pharmaceuticals (NASDAQ:LXRX) Given “Hold” Rating at Needham & Company LLC - Defense World

Nov 03, 2024
pulisher
Nov 01, 2024

Lexicon Pharmaceuticals Loses Over A Third Of Its Market Cap Post FDA Vote On Drug: Retail Sentiment Sours - MSN

Nov 01, 2024
pulisher
Nov 01, 2024

FDA panel vote leaves Lexicon’s Zynquista hopes hanging by a thread - The Pharma Letter

Nov 01, 2024
pulisher
Nov 01, 2024

Lexicon stock in selloff on FDA AdCom rebuke (LXRX:NASDAQ) - Seeking Alpha

Nov 01, 2024
pulisher
Nov 01, 2024

Lexicon Pharma Shares Slide Premarket After Negative FDA Panel Vote - MarketWatch

Nov 01, 2024
pulisher
Nov 01, 2024

Lexicon Pharmaceuticals (LXRX) PT Lowered to $5 at Leerink Partners - StreetInsider.com

Nov 01, 2024
pulisher
Nov 01, 2024

Lexicon Announces Outcome of FDA Advisory Committee for Zynquista™ (sotagliflozin) as an Adjunct to Insulin Therapy for Glycemic Control in Adults with Type 1 Diabetes and Chronic Kidney Disease - The Manila Times

Nov 01, 2024
pulisher
Oct 31, 2024

FDA advisers vote against Lexicon Pharma's add-on drug for type 1 diabetes - Reuters.com

Oct 31, 2024
pulisher
Oct 31, 2024

FDA advisers vote against Lexicon Pharma’s add-on drug for type 1 diabetes - PharmaLive

Oct 31, 2024
pulisher
Oct 31, 2024

Lexicon’s Zynquista: Negative Adcomm Vote In Type 1 Diabetes Includes Support For Revised Indication - Citeline News & Insights

Oct 31, 2024
pulisher
Oct 31, 2024

Lexicon Pharmaceuticals Halted All Day as FDA Panel Reviews Zynquista - MarketWatch

Oct 31, 2024
pulisher
Oct 31, 2024

Lexicon Pharmaceuticals Gets Negative FDA Panel Vote for Zynquista -- Update - MarketWatch

Oct 31, 2024
pulisher
Oct 31, 2024

Lexicon Pharmaceuticals Gets Negative FDA Panel Vote for Zynquista — Update - Morningstar

Oct 31, 2024
pulisher
Oct 31, 2024

Lexicon Pharmaceuticals Gets Negative FDA Panel Vote for Zynquista - Morningstar

Oct 31, 2024

Lexicon Pharmaceuticals Inc Stock (LXRX) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$70.68
price down icon 0.42%
$18.62
price up icon 0.16%
$36.06
price down icon 1.68%
$364.60
price up icon 0.01%
$196.58
price up icon 0.88%
$102.64
price up icon 0.27%
Cap:     |  Volume (24h):